September 10, 2007 - 11:00pm
By Ming Dang
Researchers at Weill Cornell Medical College may have identified a possible new treatment for Alzheimer’s diseases after concluding a preliminary, small-scale study with Baxter International. The focus of the study was Baxter’s Gammagard, an intravenous immunoglobulin treatment for patients with immunodeficiency and its effects on slowing or even stopping the progression of Alzheimer’s.
“The IVIG study was a Cornell investigator-initiated study. We conceived and designed the study and then approached Baxter and other sources for support,” said Prof. Normal Relkin, neurology and neuroscience, lead researcher at Weill Cornell Medical College.